Search

Your search keyword '"Bennet, Jaclyn"' showing total 10 results
Start Over Author "Bennet, Jaclyn"
10 results on '"Bennet, Jaclyn"'

1. Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial

Author

Evering, Teresa H, Moser, Carlee, Jilg, Nikolaus, Ritz, Justin, Wohl, David A, Li, Jonathan Z, Margolis, David, Javan, Arzhang Cyrus, Eron, Joseph J, Currier, Judith S, Daar, Eric S, Smith, Davey M, Hughes, Michael D, Chew, Kara W, Chew, Kara, Smith, David, Daar, Eric, Wohl, David, Currier, Judith, Eron, Joseph, Hughes, Michael, Giganti, Mark, Hosey, Lara, Roa, Jhoanna, Patel, Nilam, Colsh, Kelly, Rwakazina, Irene, Beck, Justine, Sieg, Scott, Li, Jonathan, Fletcher, Courtney, Fischer, William, Ignacio, Rachel Bender, Cardoso, Sandra, Corado, Katya, Jagannathan, Prasanna, Perelson, Alan, Pillay, Sandy, Riviere, Cynthia, Singh, Upinder, Taiwo, Babafemi, Gottesman, Joan, Newell, Matthew, Pedersen, Susan, Dragavon, Joan, Jennings, Cheryl, Greenfelder, Brian, Murtaugh, William, Kosmyna, Jan, Gapara, Morgan, Shahkolahi, Akbar, Lacal, Verónica, Salusso, Diego, Nuñez, Sebastian, Rodriguez, Marcelo Rodrigo, Laborde, Luciana, Papasidero, Marcelo, Wehbe, Luis, Gonzalez, Mariana, Voena, Felicitas Fernandez, Alvarez, Tomas, Lopez, Amaru, Huhn, Virginia, Nores, Ulises D'Andrea, Dieser, Pablo, Bordese, Fernando, Mussi, Marisa, de Carvalho Santana, Rodrigo, Bárbaro, Adriana Aparecida Tiraboschi, Santos, Breno, de Cássia Alves Lira, Rita, da Silva, Andre Luiz Machado, Cardoso, Sandra Wagner, Ribeiro, Maria Pia Diniz, Soliva, Nathália, Vasconcellos, Eduardo, Ribeiro, Jorge Eurico, Enéas, Miriam Amaral, Pinto, Jorge, de Morais Caporali, Julia Fonseca, Ferreira, Flávia Gomes Faleiro, Martinez, Norma Erendira Rivera, Lopez, Victor Casildo Bohorquez, Frias, Melchor Victor, Fetalvero, Krystle, Maranan, Alyxzza, Rosa, Jennifer, Coetzer, Thomas, Mohata, Maureen, Lalloo, Umesh, Madlala, Penelope, Pillay-Ramaya, Larisha, and Bennet, Jaclyn Ann

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Trials and Supportive Activities, Infectious Diseases, Prevention, Clinical Research, Emerging Infectious Diseases, Coronaviruses, 6.1 Pharmaceuticals, Good Health and Well Being, COVID-19, Monoclonal antibodies, Outpatient treatment, Clinical trial, Post COVID conditions, Long COVID, Post-acute sequelae of SARS-CoV-2 infection, ACTIV-2/A5401 Study Team, Clinical sciences, Health services and systems, Public health
Abstract

BackgroundIt is unknown if early COVID-19 monoclonal antibody (mAb) therapy can reduce risk of Long COVID. The mAbs amubarvimab/romlusevimab were previously demonstrated to reduce risk of hospitalization/death by 79%. This study assessed the impact of amubarvimab/romlusevimab on late outcomes, including Long COVID.MethodsNon-hospitalized high-risk adults within 10 days of COVID-19 symptom onset enrolled in a randomized, double-blind, placebo-controlled phase 2/3 trial of amubarvimab/romlusevimab for COVID-19 treatment. Late symptoms, assessed using a participant-completed symptom diary, were a pre-specified exploratory endpoint. The primary outcome for this analysis was the composite of Long COVID by participant self-report (presence of COVID-19 symptoms as recorded in the diary at week 36) or hospitalization or death by week 36. Inverse probability weighting (IPW) was used to address incomplete outcome ascertainment, giving weighted risk ratios (wRR) comparing amubarvimab/romlusevimab to placebo.FindingsParticipants received amubarvimab/romlusevimab (n = 390) or placebo (n = 390) between January and July 2021. Median age was 49 years, 52% were female, 18% Black/African American, 49% Hispanic/Latino, and 9% COVID-19-vaccinated at entry. At week 36, 103 (13%) had incomplete outcome ascertainment, and 66 (17%) on amubarvimab/romlusevimab and 92 (24%) on placebo met the primary outcome (wRR = 0.70, 95% confidence interval (CI) 0.53-0.93). The difference was driven by fewer hospitalizations/deaths with amubarvimab/romlusevimab (4%) than placebo (13%). Among 652 participants with available diary responses, 53 (16%) on amubarvimab/romlusevimab and 44 (14%) on placebo reported presence of Long COVID.InterpretationAmubarvimab/romlusevimab treatment, while highly effective in preventing hospitalizations/deaths, did not reduce risk of Long COVID. Additional interventions are needed to prevent Long COVID.FundingNational Institute of Allergy and Infectious Diseases of the National Institutes of Health. Amubarvimab and romlusevimab supplied by Brii Biosciences.

Published
2024

2. Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial

Author

Chew, Kara, Smith, David (Davey), Daar, Eric, Wohl, David, Currier, Judith, Eron, Joseph, Javan, Arzhang Cyrus, Hughes, Michael, Moser, Carlee, Giganti, Mark, Ritz, Justin, Hosey, Lara, Roa, Jhoanna, Patel, Nilam, Colsh, Kelly, Rwakazina, Irene, Beck, Justine, Sieg, Scott, Li, Jonathan, Fletcher, Courtney, Fischer, William, Evering, Teresa H., Ignacio, Rachel Bender, Cardoso, Sandra, Corado, Katya, Jagannathan, Prasanna, Jilg, Nikolaus, Perelson, Alan, Pillay, Sandy, Riviere, Cynthia, Singh, Upinder, Taiwo, Babafemi, Gottesman, Joan, Newell, Matthew, Pedersen, Susan, Dragavon, Joan, Jennings, Cheryl, Greenfelder, Brian, Murtaugh, William, Kosmyna, Jan, Gapara, Morgan, Shahkolahi, Akbar, Margolis, David, Lacal, Verónica, Salusso, Diego, Nuñez, Sebastian, Rodriguez, Marcelo Rodrigo, Laborde, Luciana, Papasidero, Marcelo, Wehbe, Luis, Gonzalez, Mariana, Voena, Felicitas Fernandez, Alvarez, Tomas, Lopez, Amaru, Huhn, Virginia, D'Andrea Nores, Ulises, Dieser, Pablo, Bordese, Fernando, Mussi, Marisa, de Carvalho Santana, Rodrigo, Tiraboschi Bárbaro, Adriana Aparecida, Santos, Breno, de Cássia Alves Lira, Rita, Machado da Silva, Andre Luiz, Cardoso, Sandra Wagner, Diniz Ribeiro, Maria Pia, Soliva, Nathália, Vasconcellos, Eduardo, Ribeiro, Jorge Eurico, Enéas, Miriam Amaral, Pinto, Jorge, Fonseca de Morais Caporali, Julia, Faleiro Ferreira, Flávia Gomes, Rivera Martinez, Norma Erendira, Bohorquez Lopez, Victor Casildo, Frias, Melchor Victor, Fetalvero, Krystle, Maranan, Alyxzza, Rosa, Jennifer, Coetzer, Thomas, Mohata, Maureen, Sr., Lalloo, Umesh, Madlala, Penelope, Pillay-Ramaya, Larisha, Bennet, Jaclyn Ann, Mwelase, Noluthando, Mbhele, Nokuphiwa, Petrick, Frederick, Joubert, Leonard, Mbali, Rose, Sr., Joseph, Natasha, Manentsa, Mmatsie, van der Walt, Eugene, Lawrance Masilela, Mduduzi Sandile, Zwane, Zinhle, Chiperera, Tendai, Mohapi, Lerato, Moonsamy, Suri, Singh, Usha, McHarry, Kirsten, Snyman, Elizma, Lennox, Pieter, Innes, James Craig, Letlape, Oteng, Jonkane, Olebogeng, Brumskine, William, Adonis, Tania, Sein, Ni Ni, Sebe, Modulakgotla, Vahed, Yacoob, Hussen, Nazreen Jeewa, Mitha, Ismail, Cheekati, Vasundhara, Cheekati, Purna, Lummus, Christie, Idarraga, Samuel, Kim, Andrew, Pham, David N., Kao, Wei-Hsin, Pfeffer, Michael M., Dominguez, Miriam Batule, Malik, Anju, Bryan, Anna, Arnold, Melanie, Fernandez, Idania, Karpf, Cinzia, Ruiz, Aniuska, Taylor, David, Folkens, Eric, Manne, Jennifer, Yawetz, Sigal, Keenan, Cheryl, Eziri, Emeka, Fichtenbaum, Carl, Baer, Jenifer, Trentman, Sarah, Call, Robert, Vaughan, Leroy, Milstone, Aaron, Slandzicki, Jamie Alex, Wallan, Jessica, Guillory, Clinton, Andrews, Nancy, Hughes, Leslie, Berardi, Jonathan, Arar, Celine, Quinn, Randall, Amaya, Jorge P., Gomez-Martinez, Marissa, Cantu, Luis, Betancourt-Garcia, Monica, Okeke, Nwora Lance, Burns, Charles M., Haddad, Fadi, Haddad, Victoria, Focil, Augusto, Rosas, Griselda, Moyano, Susana, Rojas, Yaneicy Gonzalez, Aswad, Ahmad, Bukhman, Yevgeniy, Jain, Manish, Bukhman, Eugene, Farah, Humam, McClain, Rebekah, Shaik, Sadia, Hatlen, Timothy, Gotur, Deepa, Surber, Joseph, Kingsley, Jeffrey, Pixler, April, Zopo, Alex, Herman, Jack, Herman, Craig, Leon, Ramon, Nikolov, Boris, Vergara, Fernando Gonzalez, Gonzalez, Ana I., Gonzalez, Noemi, Gelman, Michael, Andriunas, Olga, Jagizarov, Zarema, Westerman, Jan, Davis, David, Sherer, Donna, Dooley, Kelly, Becker, Becky, Wilkins, Adaliah, Pérez, Jose, Roman, Eloy, Fernández, Heriberto, Mocherla, Bharat, Beck, Kelly, Maldonado, Valarie, Veltman, Jennifer, Gandhi, Rajesh, Shea, Katrina, Planchon, Matthew, Herpel, Laura Bogan, Tripathi, Kaushlendra K., Day, Donald C., Pullman, John, Sr., Williams-Leber, Erin, Johnson, Misty, Hecker, Michelle, Avery, Ann, Hoover, Keila, Monlux, George W., Juneja, Elizabeth, Jr., Wernick, Arthur, Ruiz, Karelia, Hernández, Maureen, Pérez, Yadilys, Taiwo, Babafemi O., Hawkins, Claudia, Berzins, Baiba, Malvestutto, Carlos, Harber, Heather, Cicarella, Robyn, DeJesus, Edwin, Rolle, Charlotte-Paige, Free, Almena L., Pulliam, Sallie D., Weinstein, Debra, Suarez, Rosa M., Socorro, Ezequiel, Socorro, Estefania, Neytman, Gene, Easley, Raymond, Aziz, Mariam, Swiatek, Joan, Nagpal, Avish, Kompelien, Breanna, McEvoy, Kathryn, Hoover, Susan E., Lutz, Allison, Just, Jessica, Hernandez, Manuel, Victoria, Yanly B., Rodriguez, Gabriel, Pathak, Divya, Ordway, Joshua J., Heffner, Megan, Weston, Patrick, Weston, Khalilah, Choudhary, Madhu, Sullivano, Jennifer, Osiyemi, Olayemi, Izquierdo, Myriam, Torna, Odelsey, Clemency, Brian, Varughese, Renoj, Lynch, Joshua, Khodabakhshian, Aleen, Fortier, Samantha, Coyne, Christopher, Cronin, Alexandrea, Benson, Constance, Hendrickx, Steven, Ramirez, Rosemarie, Luetkemeyer, Anne, Hendler, Suzanne, Dentoni-Lasofsky, Dennis, Rathore, Mobeen, Mahmoudi, Saniyyah, Riaz, Amna, Castro, Mario, Spikes, Leslie, Hall, Chase, Oakes, Jonathan, Loftis, Amy James, Tebas, Pablo, Short, William, Dube, Michael P., Khan, Saahir, Mendez, Luis M., McGuffin, Sarah, Jonsson, Chris, Jain, Mamta K., Senthil, Smruthi, Turner-Gray, Kimberly, Mehta, Sanjay, Lewinski, Mary, Azizad, Masoud, Chow, Christopher, Nakatani, Lisa, Williamson, Derrick, Atriss, Hisham, Caloura, Matthew, Malla, Midhun, Hazard-Jenkins, Hannah, Wilkin, Aimee, Fayssoux, Jamraus, Seagle, Hannah, Presti, Rachel, Haile, Alem, Wohl, David A., Li, Jonathan Z., Eron, Joseph J., Currier, Judith S., Daar, Eric S., Smith, Davey M., Hughes, Michael D., and Chew, Kara W.

Published
2024
Full Text
View/download PDF

3. Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study

Author

de Oliveira Paiva, Hugo Diógenes, Smith, Catherin C, Brites, Carlos, Sprinz, Eduardo, Vasconcellos, Eduardo, Badal-Faesen, Sharlaa, Koen, Anthonet, Burgess, Lesley, Engelbrecht, Johannes, Vekemans, Johan, Kobielusz-Gembala, Iwona, Jones, Colin, Hirsch, Ian, Aksyuk, Anastasia, Wilkins, Deidre, Stanely, Ann Marie, Petropoulos, Christos J, Wrin, Terri, Rugieri, Sidelcina, Bennet, Jaclyn A, Greffrath, Johann, Sorio, Guilherme L, Mantyka, Jolanta, Costa Clemens, Sue Ann, Jepson, Brett, Bhorat, Qasim E, Ahmad, Abdullahi, Akhund, Tauseefullah, Aley, Parvinder K, Bansal, Himanshu, Bibi, Sagida, Kelly, Elizabeth J, Khan, Mark, Lambe, Teresa, Lombaard, Johan J, Matthews, Sam, Pipolo Milan, Eveline, Olsson, Urban, Ramasamy, Maheshi N, Moura de Oliveira Paiva, Maria Sanali, Seegobin, Seth, Shoemaker, Kathryn, Szylak, Ameena, Villafana, Tonya, Pollard, Andrew J, and Green, Justin A

Published
2024
Full Text
View/download PDF

4. Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D2EFT): an open-label, randomised, phase 3b/4 trial

Author

Matthews, Gail, Jacoby, Simone, Borok, Margaret, Eriobu, Nnakelu, Kaplan, Richard, Kumarasamy, Nagalingeswaran, Bennet, Jaclyn Ann, Avihingsanon, Anchalee, Chetchotisakd, Ploenchan, Wagner Cardoso, Sandra, Azwa, Iskandar, Losso, Marcelo, Brown, Dannae, Arlinda, Dona, Hutchinson, Jolie, Kelleher, Anthony, Cisse, Mohamed, Dao, Sounkalo, Polizzotto, Mark, Emery, Sean, Law, Matthew, Papot, Emmanuelle, Karyana, Muhammad, Lupo, Sergio, Solari, Ana Melisa, Grinsztejn, Beatriz, Wolff, Marcello, Andrade-Villanueva, Jaime, Mosqueda Gómez, Juan Luis, Chow, Ting Soo, Mohapi, Lerato, Yunihastuti, Evy, Hadi, Usman, Katu, Sudirman, Subronto, Yanri Wijayanti, Lane, H. Clifford, and Perelis, Leonardo

Published
2024
Full Text
View/download PDF

5. Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial

Author

Fichtenbaum, Carl J, Ribaudo, Heather J, Leon-Cruz, Jorge, Overton, Edgar T, Zanni, Markella V, Malvestutto, Carlos D, Aberg, Judith A, Kileel, Emma M, Fitch, Kathleen V, Van Schalkwyk, Marije, Kumarasamy, Nagalingeswaran, Martinez, Esteban, Santos, Breno Riegel, Joseph, Yvetot, Lo, Janet, Siminski, Sue, Melbourne, Kathleen, Sponseller, Craig A, Desvigne-Nickens, Patrice, Bloomfield, Gerald S, Currier, Judith S, Hoffmann, Udo, Douglas, Pamela S, Grinspoon, Steven K, Curran, Adrian, Baranauskas, Adrienne, Wilkin, Aimee, Abrams-Downey, Alexandra J, Eckard, Allison Ross, Wurcel, Alysse G, González-Cordón, Ana, Paez, Armando, Sha, Beverly E, Santos, Breno, Yoshida, Carina Beppu, Rolle, Charlotte-Paige, Somboonwit, Charurut, Funk, Connie, Gómez-Ayerbe, Cristina, Frank, Cynthia, Nixon, Daniel E, Skiest, Daniel J, Choi, David, Mushatt, David M, Rial-Crestelo, David, Perez, Deborah K, Burke, Deirdre J, dos Santos, Desirée VG, Jayaweera, Dushyantha T, Gardner, Edward M, DeJesus, Edwin, Connick, Elizabeth, Lam, Emerline G, Hecker, Emily J, Kallas, Esper G, Waters, Evan, Rhame, Frank, Sattler, Fred R, Wang, Gary P, Enrile Seedhom, Helen May, Tavares, Isabel CF, Stapleton, Jack T, Bennet, Jaclyn, Brock, James B, Scott, James, Forcht, Janet, Lama, Javier R, Valencia, Javier, Brumfield, Jennifer K, Portilla, Joaquin, Kumar, Jonathan, Navarro, Jordi, Pinto, Jorge A, Castro, Jose G, Bernardino, Jose I, Casado, Jose L, Madruga, José Valdez, Baraiaetxaburu, Josu, Berenguer, Juan, Tashima, Karen T, Ho, Ken, Costa, Laura VL, Perez Latorre, Leire, Mohapi, Lerato, López-González, L, Fantry, Lori E, Domínguez-Domínguez, Lourdes, Martín-Carbonero, Luz, Cornelissen, Lynne M, Jain, Mamta K, Masiá, Mar, Lacerda, Marcus VG, Saumoy, Maria, Villalobos-Hernández, Marina, and Mall, Mark

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Clinical Research, HIV/AIDS, Clinical Trials and Supportive Activities, Prevention, Infectious Diseases, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Infection, Good Health and Well Being, Adult, Anti-Retroviral Agents, CD4 Lymphocyte Count, CD4-CD8 Ratio, Cross-Sectional Studies, Female, HIV Infections, Humans, Male, Middle Aged, Randomized Controlled Trials as Topic, HIV, statins, pitavastatin calcium, antiretroviral therapy, CD4 cell count, CD4/CD8 ratio, REPRIEVE, cardiovascular disease, REPRIEVE Investigators, Biological Sciences, Medical and Health Sciences, Microbiology, Biological sciences, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundPatterns of antiretroviral therapy (ART) use and immunologic correlates vary globally, and contemporary trends are not well described.MethodsThe REPRIEVE trial (Randomized Trial to Prevent Vascular Events in HIV) enrolled persons with human immunodeficiency virus (HIV) who were aged 40-75 years, receiving ART, and had low-to-moderate cardiovascular disease risk. ART use was summarized within Global Burden of Disease (GBD) super-regions, with adjusted linear and logistic regression analyses examining associations with immune parameters and key demographics.ResultsA total of 7770 participants were enrolled, with a median age of 50 years (interquartile range, 45-55 years); 31% were female, 43% were black or African American, 15% were Asian, 56% had a body mass index >25 (calculated as weight in kilograms divided by height in meters squared), and 49% were current or former smokers. The median CD4 T-cell count was 620/µL (interquartile range, 447-826/ µ L), and the median duration of prior ART use, 9.5 years (5.3-14.8) years. The most common ART regimens were nucleoside/nucleotide reverse-transcriptase inhibitor (NRTI) plus nonnucleoside reverse-transcriptase inhibitor (43%), NRTI plus integrase strand transfer inhibitor (25%), and NRTI plus protease inhibitor (19%). Entry ART varied by GBD region, with shifts during the trial enrollment period. In adjusted analyses, entry CD4 cell count and CD4/CD8 ratio were associated with GBD region, sex, entry regimen, duration of ART, and nadir CD4 cell count; CD4 and CD8 cell counts were also associated with body mass index and smoking status.ConclusionsThere were substantial variations in ART use by geographic region and over time, likely reflecting the local availability of specific medications, changes in treatment guidelines and provider/patient preferences. The analyses of CD4 cell counts and CD4/CD8 ratios may provide valuable insights regarding immune correlates and outcomes in people living with HIV.Clinical trials registrationNCT02344290.

Published
2020

6. Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial

Author

Adilaa, Oyunchimeg, Alexandru, Sofia, Bellenger, Katharine, Bennet, Jaclyn, Bennet, Deborah, Bindroo, Priyanka, Borisagar, Ghanshyam, Cook, Claire, Dalai, Doljinsuren, Davis, Andrew, de Jong, Bouke, Dodds, Wendy, Duckworth, Lynette, Gahima, Nonhlanhla, Gebreegziabher, Belay, Goldfeld, Anne, Hanifa, Mahmud, Hughes, Gareth, Kimuli, Ivan, Komrska, Jan, Lomtadze, Nino, Murphy, Brendan, Mwelase, Thando, Nalunjogi, Joanitah, Patel, Leena, Pirlog, Irina, Qawiy, Ishmael, Rauchenberger, Mary, Rigouts, Leen, Roach, Carol, Rosu, Laura, Santos-Filho, Ezio, Senguttuvan, Thirumaran, Sisay, Million, Sridhar, Rathinam, Srinivasulu, Vignes, Teferi, Mekonnen, Teklu, Helen, Tsegeen, Narangarav, van Amsterdam, Odette, White, Lisa, Whitney, Johanna, Zagd, Chuluunbaatar, Goodall, Ruth L, Meredith, Sarah K, Nunn, Andrew J, Bayissa, Adamu, Bhatnagar, Anuj K, Bronson, Gay, Chiang, Chen-Yuan, Conradie, Francesca, Gurumurthy, Meera, Kirenga, Bruce, Kiria, Nana, Meressa, Daniel, Moodliar, Ronelle, Narendran, Gopalan, Ngubane, Nosipho, Rassool, Mohammed, Sanders, Karen, Solanki, Rajesh, Squire, S Bertel, Torrea, Gabriela, Tsogt, Bazarragchaa, Tudor, Elena, Van Deun, Armand, and Rusen, I D

Published
2022
Full Text
View/download PDF

7. A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial

Author

Solomon, Sunil S, Wagner-Cardoso, Sandra, Smeaton, Laura, Sowah, Leonard A, Wimbish, Chanelle, Robbins, Gregory, Brates, Irena, Scello, Christine, Son, Annie, Avihingsanon, Anchalee, Linas, Benjamin, Anthony, Donald, Nunes, Estevão Portela, Kliemann, Dimas A, Supparatpinyo, Khuanchai, Kityo, Cissy, Tebas, Pablo, Bennet, Jaclyn Ann, Santana-Bagur, Jorge, Benson, Constance A, Van Schalkwyk, Marije, Cheinquer, Nelson, Naggie, Susanna, Wyles, David, and Sulkowski, Mark

Published
2022
Full Text
View/download PDF

8. Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial

Author

Goodall, Ruth L, primary, Meredith, Sarah K, additional, Nunn, Andrew J, additional, Bayissa, Adamu, additional, Bhatnagar, Anuj K, additional, Bronson, Gay, additional, Chiang, Chen-Yuan, additional, Conradie, Francesca, additional, Gurumurthy, Meera, additional, Kirenga, Bruce, additional, Kiria, Nana, additional, Meressa, Daniel, additional, Moodliar, Ronelle, additional, Narendran, Gopalan, additional, Ngubane, Nosipho, additional, Rassool, Mohammed, additional, Sanders, Karen, additional, Solanki, Rajesh, additional, Squire, S Bertel, additional, Torrea, Gabriela, additional, Tsogt, Bazarragchaa, additional, Tudor, Elena, additional, Van Deun, Armand, additional, Rusen, I D, additional, Adilaa, Oyunchimeg, additional, Alexandru, Sofia, additional, Bellenger, Katharine, additional, Bennet, Jaclyn, additional, Bennet, Deborah, additional, Bindroo, Priyanka, additional, Borisagar, Ghanshyam, additional, Cook, Claire, additional, Dalai, Doljinsuren, additional, Davis, Andrew, additional, de Jong, Bouke, additional, Dodds, Wendy, additional, Duckworth, Lynette, additional, Gahima, Nonhlanhla, additional, Gebreegziabher, Belay, additional, Goldfeld, Anne, additional, Hanifa, Mahmud, additional, Hughes, Gareth, additional, Kimuli, Ivan, additional, Komrska, Jan, additional, Lomtadze, Nino, additional, Murphy, Brendan, additional, Mwelase, Thando, additional, Nalunjogi, Joanitah, additional, Patel, Leena, additional, Pirlog, Irina, additional, Qawiy, Ishmael, additional, Rauchenberger, Mary, additional, Rigouts, Leen, additional, Roach, Carol, additional, Rosu, Laura, additional, Santos-Filho, Ezio, additional, Senguttuvan, Thirumaran, additional, Sisay, Million, additional, Sridhar, Rathinam, additional, Srinivasulu, Vignes, additional, Teferi, Mekonnen, additional, Teklu, Helen, additional, Tsegeen, Narangarav, additional, van Amsterdam, Odette, additional, White, Lisa, additional, Whitney, Johanna, additional, and Zagd, Chuluunbaatar, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results